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Summary Six hundred and sixty-three patients were followed with serial serum CEA measurements in
addition to routine clinical surveillance after radical resection of colorectal carcinoma. Of 626 available for
analysis, 366 (58.4%) remained clinically free of recurrence and had a normal CEA (<20ngml-1) throughout
and 89 (14.2%) had a temporary non-progressive rise in CEA with no evidence of secondary disease. Of 171
patients who developed proven or suggestive recurrence, 114 had a preceding rise in the serum CEA and in
further 21 the CEA rose simultaneously with recurrence. In 36 patients secondary disease was detected while
the CEA was still within normal limits. CEA was more effective as an early index of distant metastasis, thus
in 76% of those patients with a preceding rise in CEA, the secondary disease was disseminated, whereas only
20% had localised recurrence. The pattern of rise in CEA was of no practical value in distinguishing localised
from distant recurrence.
When carcinoembryonic antigen (CEA) was first
identified by Gold & Freedman (1965a, b) it was
thought to be specific for gastrointestinal
neoplasms and foetal tissues. The development of a
serum assay by Thompson et al. (1969) appeared to
offer a blood test which would be of value in the
diagnosis of alimentary cancers. Much of the initial
enthusiasm for the test evaporated as it became
apparent that serum CEA testing lacked specificity
and sensitivity (Sugarbaker et al., 1976; Sorokin et
al., 1974) and it has since been shown to be of
minimal value in the primary diagnosis of gastro-
intestinal disease (Hine et al., 1978). However, in
the post-operative surveillance of patients who have
had radical resections of colorectal carcinomas,
several studies have shown that a rise in the serum
CEA precedes clinical recurrence in the majority of
cases (Sorokin et al., 1974; Mach et al., 1974;
Booth et al., 1974; Herrera et al., 1976; Wood et
al., 1978). In some instances the lead-time has been
up to 29 months (Sorokin et al., 1974). Generally,
these studies have been performed in units
specialising in the follow-up of large bowel cancer
and the aim of the present study was to assess the
usefulness of serum CEA testing alongside routine
surveillance in general surgical clinics.
Patients and methods
The study included 663 patients (367 males, 296
females) who had undergone radical surgery for
colorectal carcinoma. In 290 the primary was in the
rectum or rectosigmoid and in 373 it was colonic or
caecal. Squamous cell carcinomas of the anus were
excluded as were tumours originating in the
appendix. Thirty-five surgeons from 8 different
hospitals in the West Midlands contributed cases.
All patients were under 70 years of age at the time
of surgery (mean age 59.0 years) and CEA
screening was usually commenced between 3 and 6
months after operation, although some individuals
were admitted to the trial when resection had been
performed up to 3 years previously. Histological
grading of the primary tumour (Dukes, 1932) was
A in 38, B in 377 and C in 248 cases. Patients were
followed for a mean of 39.7 months post-
operatively.
Patients were generally reviewed at 3 monthly
intervals during the first two post-operative years
or more frequently when necessary. Thereafter, the
interval between visits increased to 6 or 12 months
in parallel with the follow-up practice of the
surgeon involved. Full clinical examination
including sigmoidoscopy was performed and the
diagnosis of recurrence was primarily made on the
basis of symptoms and signs of disease confirmed
by other investigations when indicated (e.g. liver
scan, bone scan, biopsy). Abnormal haematological
or biochemical tests alone were not regarded as
evidence of recurrence. Blood was taken for CEA
estimation at each follow-up visit. Serum was
separated from the blood within 2 h and despatched
to a central laboratory within 24h. On arrival
specimens were stored at -20°C until assayed.
CEA was measured in the unextracted serum by
a double antibody radio-immunoassay as developed
by Egan et al. (1972) and adapted by Laurence et
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al. (1972). The inter- and intra-assay variation of
the method was found to be < 10%. An upper limit
of 15ngml-P will include 99% of a normal
population and in the present study a level of
>20ngml- I was regarded as abnormal.
Patients in whom routine screening showed a
CEA concentration of >20ngml-1 were recalled to
clinic within 2 months of the date of the first
sample. Thorough clinical examination was
undertaken including sigmoidoscopy. If this
indicated recurrent malignancy, confirmatory
investigations were ordered and management was
initiated appropriate to the results. When clinical
examination failed to reveal malignancy, the
subsequent course of events depended on the degree
of elevation of the CEA. If the level was
>20ngml-1 but <35ngml-1, the test was
repeated at monthly intervals until it fell below
20ngml-1 or rose above 35ngml-1. All patients
with levels >35ngml-1 and no clinical evidence of
recurrence had a further CEA estimation, full blood
count, erythrocyte sedimentation rate, liver function
tests, barium enema, chest X-ray and isotope
and/or ultrasound liver scan, together with bone
scan and colonoscopy where indicated. If
recurrence was diagnosed from the results of these
investigations then appropriate management was
instituted. Those patients with at least two
progressively rising CEA values of >35ngml-1 but
no other definite evidence of recurrent malignancy
were randomised in a prospective trial of cytotoxic
therapy (Hine & Dykes, 1984).
Results
Of the 663 patients in the screening programme 37
were excluded from the final analysis (Table I). Of
these, 21 had not a CEA measurement for over one
year, although they continued to attend clinic, 6
were lost to clinical follow-up and 5 others were
removed from the trial. Removal followed the
development of unassociated conditions such as
alcoholic cirrhosis which interfered with the
interpretation of a significant CEA rise (3 patients)
and in 2 patients the onset of psychiatric illness
made the use of cancer chemotherapy inadvisable.
A further 5 patients died during the follow-up
period from conditions other than their cancer.
Three hundred and sixty-six patients (58.4%) of
the 626 available for analysis remained clinically
free of recurrent colorectal cancer and had a
normal CEA throughout the follow-up period.
However, 2 of these developed second malignancies
without a rise in serum CEA, one a breast
carcinoma and the other chronic lymphocytic
leukaemia.
In another 89 patients (14.2%) there was a
temporary rise in serum CEA in the absence of
malignancy. Most of these patients had CEA values
between 20.0 and 29.9 ngml1 but in 5 the CEA
exceeded 50.0ngml-1. Eleven patients had 3 or
more consecutive elevated values and although 3 of
these patients had chronic inflammatory disease
there was no obvious cause for the high CEA in the
remaining 8.
Table I Outcome in 663 patients included in screening programme
Sub-totals
Category (%)
Normal CEA throughout
Clinically cancer-free
Unassociated second malignancy
Temporary, non-progressive rise in CEA,
no recurrence
Rise in CEA before recurrence
Randomised
not randomised
Rise in CEA simultaneous with recurrence
Recurrence while CEA within normal limits
Non-cancer deaths
Lost
Removed from trial
Total
364
2 366 (58.4)
89 (14.2)
52
62 114 (18.2)
21 (3.4)
36 (5.8)
626 (100.0)
5
27
5 37
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In 2 patients in whom CEA was normal at the
time of recurrence, a single high titre was recorded
6 and 12 months respectively before clinical
recurrence became apparent. Nine other patients
showed a non-progressive elevation of CEA over
several months which foreshadowed a progressive
rise.
A progressive rise in CEA was seen in 114
patients (18.2%) of whom 62 were found to have
either secondary disease (59) or a second colonic
primary (3) during the period of investigation which
followed the first elevated level of CEA. The other
52 patients were included in a prospective
randomised trial of chemotherapy and of these all
but one has developed clinical recurrence during a
5-year follow-up (Hine & Dykes, 1984). The
exception was a patient with two levels of CEA
rising for 41ngml-I to 63ngml-1. A further test
two months later indicated a CEA level of
88 ngml- but thereafter it fell to normal levels
(<20 ngml-1) and has remained so for 5 years.
The patient has not developed any clinical evidence
of recurrence.
In 21 patients (3.4%) in the screening
programme, clinical recurrence was apparent at the
time of the first CEA rise and in 36 (5.8%)
secondary disease was detected while the serum
CEA was still within normal limits.
An asymptomatic rise in CEA concentration
usually indicated the presence of tumour in the
liver, whereas when clinical evidence came first, the
growth was more commonly local (Table II). The
rise in CEA concentration was earlier than clinical
recurrence in 82% of hepatic recurrences, in 65%
of other distant metastases, but in only 43% of
those recurring locally.
In the 62 patients where early recurrence after
the CEA rise prevented inclusion in the therapeutic
study, the lead time was longer when the disease
was disseminated than when there was local
recurrence (Table III). The rate of rise was
Table III CEA lead-time in relation to site of
recurrence in 62 patients with preceding rise in
CEA but not randomised in chemotherapy trial
Median lead time
Site No. patients (weeks)
Local 15 8
Second
primary 3 18
Hepatic 33 21
Brain 3 17
Bone 2 39
Lung 3 17
Ovary 1 13
Distant lymph
nodes 2 17
examined in these patients, but was not possible to
identify before recurrence intervened in 36% and
67% respectively of those with disseminated and
local disease. The rate of rise was then faster in the
presence of disseminated rather than local disease,
18 of 28 of the former then reaching lOOngml-l
within 6 months against 2 of 6 with local disease
but this difference was not significant.
Thus after a mean post-operative follow-up
period of 39.7 months, 455 (72.7%) of 626 patients
remained free of clinical recurrence. Of the 171 with
evident cancer or rising CEA concentrations, in 114
(67%) the CEA elevation was the first evidence for
further malignancy with a median lead-time of 30
weeks.
Discussion
These results confirm that regular CEA testing of
patients after radical resection of colorectal
Table II Timing of CEA rise in 171 patients compared with the site of recurrence
Site ofrecurrence
Other Second None to
No. Local Hepatic distant primary date
Preceding rise in CEA
(a) Randomised patients 52 8 (15) 37 (71) 6 (12) 0 1 (2)
(b) Non-randomised 62 15 (24) 33 (53) 11 (18) 3 (5) 0
patients
(a) and (b) 114 23 (20) 70 (61) 17 (15) 3 (3) 1 (1)
Simultaneous rise in
CEA 21 11 (52) 3 (14) 7 (34) 0 0
No rise in CEA 36 20 (55) 12 (33) 2 (6) 2 (6) 0
Percentages in parentheses.
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carcinoma will predict the development of clinical
recurrence in the majority of patients. Similar
results were obtained by Wood et al. (1978) who
found that raised CEA levels preceded the detection
of recurrence in 78% of 41 patients by 2 to 28
months (median=4 months). The longer lead-time
in the present study may reflect either a difference
in assay technique and choice of pathological level,
a difference in the frequency of follow-up or some
other clinical factor. Other smaller studies have also
shown that a CEA rise was the first indication of
recurrence in the majority of patients developing
secondary disease (Mach et al., 1974; Booth et al.,
1974; Herrera et al., 1976).
In the present study there was a proven or
suggestive recurrence rate of 27.3% after a mean
follow-up of 39.7 months. Birmingham Regional
Cancer Registry figures show an uncorrected
mortality rate of - 52% at 40 months after
diagnosis of radically treated colorectal cancer
(Waterhouse, 1974). Mortality must of necessity be
lower than recurrence, and the substantial
difference between these results is surprising.
There appear to be three possible explanations
for this difference. First, some of the surgeons did
not enter all eligible patients into the study and
there could, therefore, be some patient selection,
but this deficiency was neither great nor frequent
and seems unlikely. Second, the surgeons
participating in the study were clearly interested in
bowel cancer and the results may be better than the
regional average, though the difference is large for
this explanation. Third, there was a restriction on
entry in that no patient entered the trial until at
least 3-months had elapsed from the date of
operation. Early post-operative deaths are excluded
therefore from our figures. Furthermore, a few
individuals were entered up to 3-years post-
operatively when the rate of recurrence has dropped
markedly. Thus, our figures are not compatible
with those of the Cancer Registry and the present
data may reasonably be regarded as representative.
Temporary, non-progressive elevations of CEA
were seen in 14.2% of patients under surveillance
and the patient in whom a progressive rise in CEA
gave false information about recurrent disease is
probably an extreme example of this same
phenomenon. The problem of false positive rises in
CEA has been recognised before (Rittgers et al.,
1978). Lowering the pathological level may enable
earlier treatment to be given but more false
positives would be expected. On the other hand,
raising the pathological level to increase the
specificity of the test would greatly reduce the yield
from CEA surveillance. In this study, strict criteria
of two determinations greater than 35ngml-1
and progressively rising have been enforced. This
produced one false positive in 114 which may be
regarded as an acceptable degree of specificity.
The potential benefit of any system of
surveillance lies in allowing an improvement in
therapy. In colorectal cancer this can only mean
either early detection and removal of local
recurrence or metachronous tumour, or more
effective chemotherapy in disseminated disease.
Moertel et al. (1978) believe the CEA test to be of
little value in predicting locally recurrent lesions, a
view that has more recently been challenged (Staab
et al., 1978). In this latter study, analysis of the
rising CEA curves suggested that slow rises were
associated with local disease, whereas faster rises
indicated dissemination. Wood et al. (1980) also
found that if a rising CEA remained below
75ngml- for at least 12 months, the site of
recurrence was likely to be local, whereas in
patients with metastatic disease serum concen-
trations reached 100ngml1 within 6 months of the
first raised level. The present prospective study,
however, suggests that this information may be of
little practical value in the selection of patients for
second-look laparotomy since in two thirds of those
with localised recurrence the CEA trend was not
apparent at the time the tumour became clinically
obvious and in the 6 patients where the rate of rise
was determined it was rapid in two. Faced with this
uncertainty, the clinician would do better to use
more conventional methods of establishing the
presence of local disease when asymptomatic
patients develop elevated CEA concentration.
Nevertheless, in this study 26 patients with localised
recurrence or a second primary had a preceding rise
in CEA. Having established the presence of disease
and assessed the operability some such patients may
benefit from further surgery.
The present results, however, do confirm that
progressive elevation of serum levels generally
indicates disseminated disease, most commonly
hepatic. It would appear more logical to consider a
systemic approach such as chemotherapy when a
significant rise occurs in serum CEA concentration.
In advanced disease a clinical response rate to
chemotherapy of over 40% has been reported
(Moertel et al., 1975) although this has not been
matched by an improvement in survival of treated
patients (Buroker et al., 1978). In a study from our
unit when cytotoxic therapy was given at the
earliest evidence of recurrence, as indicated by a
rise in CEA, a similar picture emerged with no
overall benefit to treated patients in terms of
survival (Hine & Dykes, 1984). However, a
subgroup of patients who showed a significant fall
in CEA seemed to derive clinical benefit from early
therapy (Hine & Dykes, 1984). Such patients
together with those in whom surgically accessiblePOST-OPERATIVE CEA TESTING IN COLORECTAL CANCER 693
disease is suggested by CEA demonstrate the
possible value of a CEA surveillance programme
after radical surgery for colorectal cancer.
We are grateful to the surgeons who contributed patients
to this study. The work was supported by a grant from
the Medical Research Council.
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